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BACKGROUND
E-cigarettes are commonly used in attempts to stop smoking, but evidence is limited 
regarding their effectiveness as compared with that of nicotine products approved as 
smoking-cessation treatments.
METHODS
We randomly assigned adults attending U.K. National Health Service stop-smoking 
services to either nicotine-replacement products of their choice, including product 
combinations, provided for up to 3 months, or an e-cigarette starter pack (a second-
generation refillable e-cigarette with one bottle of nicotine e-liquid [18 mg per milli-
liter]), with a recommendation to purchase further e-liquids of the flavor and strength 
of their choice. Treatment included weekly behavioral support for at least 4 weeks. The 
primary outcome was sustained abstinence for 1 year, which was validated biochemi-
cally at the final visit. Participants who were lost to follow-up or did not provide bio-
chemical validation were considered to not be abstinent. Secondary outcomes included 
participant-reported treatment usage and respiratory symptoms.
RESULTS
A total of 886 participants underwent randomization. The 1-year abstinence rate was 
18.0% in the e-cigarette group, as compared with 9.9% in the nicotine-replacement 
group (relative risk, 1.83; 95% confidence interval [CI], 1.30 to 2.58; P<0.001). Among 
participants with 1-year abstinence, those in the e-cigarette group were more likely 
than those in the nicotine-replacement group to use their assigned product at 52 weeks 
(80% [63 of 79 participants] vs. 9% [4 of 44 participants]). Overall, throat or mouth 
irritation was reported more frequently in the e-cigarette group (65.3%, vs. 51.2% in 
the nicotine-replacement group) and nausea more frequently in the nicotine-replace-
ment group (37.9%, vs. 31.3% in the e-cigarette group). The e-cigarette group reported 
greater declines in the incidence of cough and phlegm production from baseline to 52 
weeks than did the nicotine-replacement group (relative risk for cough, 0.8; 95% CI, 
0.6 to 0.9; relative risk for phlegm, 0.7; 95% CI, 0.6 to 0.9). There were no significant 
between-group differences in the incidence of wheezing or shortness of breath.
CONCLUSIONS
E-cigarettes were more effective for smoking cessation than nicotine-replacement 
therapy, when both products were accompanied by behavioral support. (Funded by the 
National Institute for Health Research and Cancer Research UK; Current Controlled 
Trials number, ISRCTN60477608.)
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Switching completely from ciga-rette smoking to e-cigarette use would be expected to reduce risks to health.1-3 There 
are questions about risks and benefits of use of 
e-cigarettes for different purposes, but an impor-
tant clinical issue is whether e-cigarette use in a 
quit attempt facilitates success, particularly as 
compared with the use of nicotine-replacement 
therapy.
A Cochrane review showed that e-cigarettes 
with nicotine were more effective for smoking 
cessation than nicotine-free e-cigarettes.4 A trial 
that compared e-cigarettes with nicotine patches 
for smoking cessation used cartridge e-cigarettes 
with low nicotine delivery and no face-to-face 
contact. It showed similar low efficacy for both 
treatments.5 (For further details of previous trials, 
see the Supplementary Appendix, available with 
the full text of this article at NEJM.org.) Our 
trial evaluated the 1-year efficacy of refillable 
e-cigarettes as compared with nicotine replace-
ment when provided to adults seeking help to 
quit smoking and combined with face-to-face 
behavioral support.
Me thods
Design and Oversight
We conducted a two-group, pragmatic, multi-
center, individually randomized, controlled trial. 
National Health Service (NHS) stop-smoking 
services are available free across the United 
Kingdom.6 This trial was conducted in three 
service sites from May 2015 through February 
2018. The Health and Lifestyle Research Unit 
that delivers the service for two London boroughs 
(Tower Hamlets and City of London), along with 
the Leicester and East Sussex services, recruited 
participants and delivered the interventions. Par-
ticipating services included trial information in 
their advertising. Participants were also recruited 
through social media. Adult smokers were in-
vited to participate if they were not pregnant or 
breast-feeding, had no strong preference to use 
or not to use nicotine replacement or e-ciga-
rettes, and were currently not using either type 
of product.
The trial was approved by the National Re-
search Ethics Service (reference number, 14/LO/ 
2235). Collective unblinded data were seen only 
for the purposes of the meetings of the data 
monitoring and ethics committee. Data analyses 
were conducted with blinding to treatment as-
signments. All the authors contributed to the 
trial design, participated in the interpretation of 
the data, vouch for their completeness and ac-
curacy, and made the decision to submit the 
manuscript for publication. All the authors vouch 
for the fidelity of the trial to the protocol, avail-
able at NEJM.org.
Procedures
Smokers were provided with trial information, 
prescreened for eligibility, and, if eligible, invit-
ed to a baseline session. There, eligibility was 
confirmed, written informed consent and base-
line data were obtained, and participants set up 
their quit date (normally the following week).7
Randomization took place on the quit date to 
limit differential dropout. Randomization se-
quences (1:1 ratio in permuted blocks of 20, 
stratified according to trial site) were generated 
with the use of a pseudorandom number genera-
tor in Stata software and were embedded into an 
application that only revealed the next treatment 
assignment once a participant had been entered 
into the database.
Product use started immediately after ran-
domization. All the participants received the same 
multisession behavioral support as per U.K. stop-
smoking service practice.7,8 This support involved 
weekly one-on-one sessions with local clinicians, 
who also monitored expired carbon monoxide 
levels for at least 4 weeks after the quit date.
Participants were contacted by telephone at 
26 and 52 weeks. Interviewers asked about prod-
uct use and thus were aware of the treatment 
assignments. Participants who reported absti-
nence or a reduction in smoking of at least 50% 
at 52 weeks were invited back to provide a car-
bon monoxide reading. Participants were com-
pensated £20 ($26 U.S.) for their travel and time 
at the 52-week validation visit.
Nicotine-Replacement Group
Participants were informed about the range of 
nicotine-replacement products (patch, gum, loz-
enge, nasal spray, inhalator, mouth spray, mouth 
strip, and microtabs) and selected their pre-
ferred product. Use of combinations was encour-
aged, typically the patch and a faster-acting oral 
product. Participants were also free to switch 
The New England Journal of Medicine 
Downloaded from nejm.org at QUEEN MARY AND WESTFIELD COLLEGES on January 31, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 3
E-Cigarettes vs. Nicotine-Replacement Ther apy
products. The way that nicotine replacement 
was provided differed slightly among trial sites 
(see the Supplementary Appendix). Supplies were 
provided for up to 3 months, as per standard 
practice. The cost to the NHS of a 3-month supply 
of a single nicotine-replacement product is cur-
rently approximately £120 ($159 U.S.).
E-Cigarette Group
A starter pack, called One Kit (Aspire, U.K. Ecig 
Store), was provided to facilitate initial use and 
teach participants how to use refillable e-ciga-
rette products, along with one 30-ml bottle of 
Tobacco Royale flavor e-liquid purchased from 
U.K. Ecig Store, containing nicotine at a concen-
tration of 18 mg per milliliter. The kit had a 
2.1-ohm atomizer and 650-mAh battery. During 
the trial, the company discontinued this kit, so 
One Kit 2016 (Innokin, U.K. Ecig Store), with a 
1.5-ohm atomizer and 1000-mAh battery, was 
used for 42 participants. Participants were asked 
to purchase their future e-liquid online or from 
local vape shops and to buy a different e-ciga-
rette device if the one supplied did not meet their 
needs. They were encouraged to experiment with 
e-liquids of different strengths and flavors. 
Those who were unable to obtain their own sup-
ply were provided with one further 10-ml bottle, 
but this was not offered proactively. Participants 
received oral and written information on how to 
operate the e-cigarette.
The original One Kit, including five atomizers, 
U.K. adapter, spare battery, and e-liquid, was 
purchased wholesale for £19.40 ($26 U.S.). The 
cost of One Kit 2016, including the same extras, 
was £30.25 ($40 U.S.).
Participants in the e-cigarette group and 
those in the nicotine-replacement group were 
asked to sign a commitment to not use the non-
assigned treatment for at least 4 weeks after 
their quit date. This was to minimize contami-
nation between the trial groups.
Measures
At trial visits, the following data were recorded: 
smoking status, expired carbon monoxide level 
(at baseline, 4 weeks, and 52 weeks), use and 
ratings of trial products, ratings of withdrawal 
symptoms (weeks 1 through 6), adverse reac-
tions (presence or absence of nausea, sleep dis-
turbance, and throat or mouth irritation), and 
respiratory symptoms (presence or absence of 
shortness of breath, wheezing, cough, and 
phlegm). The Supplementary Appendix provides 
further details of trial measures.
The primary outcome was 1-year sustained 
abstinence, calculated in accordance with the 
Russell Standard9 as a self-report of smoking no 
more than five cigarettes from 2 weeks after the 
target quit date, validated biochemically by an 
expired carbon monoxide level of less than 8 ppm 
at 1-year follow-up and not contradicted by any 
previous self-report or validation result. Carbon 
monoxide validation is the standard measure in 
trials assessing nicotine-containing products (see 
the Supplementary Appendix). Participants who 
died (one in each group) were excluded. Partici-
pants who were lost to follow-up or did not 
provide biochemical validation were classified as 
not being abstinent in the primary analysis.
Secondary abstinence outcomes included sus-
tained abstinence from 26 to 52 weeks, at 4 weeks, 
and at 26 weeks and the percentage of partici-
pants without sustained abstinence from 26 to 
52 weeks who reduced their cigarette consump-
tion by at least 50%. We also assessed 7-day 
abstinence at 4, 26, and 52 weeks. In addition, 
we compared the trial groups with respect to 
relapse rate and time to relapse and with respect 
to the measures listed above.
Statistical Analysis
We calculated that a sample of 886 participants 
would provide the trial with 95% power (at a 
two-sided alpha level of 0.05) if the true percent-
ages of 1-year abstinence were 23.8% in the 
e-cigarette group and 14.0% in the nicotine-
replacement group (relative risk, 1.7). Since trial 
setup, the abstinence rate in stop-smoking ser-
vice clinics declined to 10%, but the sample of 
886 participants would provide 85% power if the 
percentages were 17.0% and 10.0% in the re-
spective groups.
The primary and secondary abstinence out-
comes were analyzed by regression of smoking 
status at each time point onto trial group. Pri-
mary analyses were adjusted for trial center to 
account for the stratification factor. In sensitiv-
ity analyses, each model was further adjusted for 
baseline covariates selected with the use of step-
wise regression. Binary regressions were con-
ducted by means of the generalized linear model 
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with binomial distribution and logarithmic link 
to estimate the relative risk for e-cigarettes as 
compared with nicotine-replacement therapy.
To assess the effect of missing data on the 
primary outcome, we conducted four prespecified 
sensitivity analyses, which excluded participants 
who did not attend at least one behavioral-sup-
port session, excluded participants who used the 
nonassigned product for at least 5 consecutive 
days, excluded participants who did not com-
plete the 52-week follow-up, and imputed miss-
ing information with the use of multiple imputa-
tion by chained equations.10 Missing data were 
imputed for 136 participants in each group, and 
50 data sets were imputed.
We also estimated mean differences and 95% 
confidence intervals between trial groups in 
product ratings and in change scores between 
baseline and follow-up time points in withdrawal 
symptoms, as well as between-group differences 
in the percentage of participants who had ad-
verse reactions or respiratory symptoms, using 
binomial regression with adjustment for trial 
center (see the statistical analysis plan, available 
with the protocol at NEJM.org). Analyses were 
conducted with the use of Stata software, ver-
sion 15 (StataCorp).
R esult s
Participants
A total of 2045 clients of stop-smoking services 
were screened, and 886 underwent randomiza-
tion (439 to the e-cigarette group and 447 to the 
nicotine-replacement group). Of the randomly 
assigned participants, 78.8% completed the 52-
week follow-up (Fig. 1). The sample was com-
posed largely of middle-aged smokers, with 
40.7% entitled to free prescriptions (a marker of 
social disadvantage or poor health) (Table 1, and 
Table S1 in the Supplementary Appendix).
Effects of Treatment on Abstinence
The rate of sustained 1-year abstinence was 
18.0% in the e-cigarette group and 9.9% in the 
nicotine-replacement group (relative risk, 1.83; 
95% confidence interval [CI], 1.30 to 2.58; 
P<0.001) (Table 2). The absolute difference in the 
1-year abstinence rate between the two groups 
was 8.1 percentage points, resulting in a number 
needed to treat for one additional person to have 
sustained abstinence of 12 (95% CI, 8 to 27). The 
result did not change substantially in the four 
sensitivity analyses (relative risk, 1.75 to 1.85; 
P≤0.001 for all comparisons) (Table S2 in the 
Supplementary Appendix). Abstinence rates were 
higher in the e-cigarette group than in the nico-
Figure 1. Screening, Randomization, and Follow-up.
Reasons for ineligibility in 463 of the 2045 persons screened are detailed  
in Table S11 in the Supplementary Appendix. Of the 438 participants in the 
e-cigarette group who were included in the primary analysis, 3 stopped 
treatment and declined follow-up and 13 stopped treatment and permitted 
follow-up. Of the 446 participants in the nicotine-replacement group who 
were included in the primary analysis, 5 stopped treatment and declined 
follow-up and 36 stopped treatment and permitted follow-up.
886 Underwent randomization
2045 Clients of stop-smoking services
were screened for eligibility
998 Were excluded
463 Were not eligible
535 Did not attend the 
first session
1047 Attended first session
and were rescreened
161 Were excluded
14 Were not eligible
147 Were not present for
randomization
439 Were assigned to the e-cigarette
group
432 Attended ≥1 session after
quit date
447 Were assigned to the nicotine-
replacement group
438 Attended ≥1 session after
quit date
376 Completed 4-wk follow-up 356 Completed 4-wk follow-up
352 Completed 6-mo follow-up 337 Completed 6-mo follow-up
356 Completed 12-mo follow-up 342 Completed 12-mo follow-up
438 Were included in primary analysis
1 Died during the trial
446 Were included in primary analysis
1 Died during the trial
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tine-replacement group at all time points (Table 2, 
and Table S3 in the Supplementary Appendix).
We conducted a post hoc analysis, in which 
participants with 1-year abstinence who used 
nonassigned products (see the Supplementary 
Appendix) were removed from the sample (3% 
[2 of 79] in the e-cigarette group were using 
nicotine replacement and 20% [9 of 44] in the 
nicotine-replacement group were using e-ciga-
rettes). This resulted in a 1-year abstinence rate 
of 17.7% in the e-cigarette group, as compared 
with 8.0% in the nicotine-replacement group 
(relative risk, 2.21; 95% CI, 1.52 to 3.22).
Among participants in whom full abstinence 
Characteristic
E-Cigarettes 
(N = 438)
Nicotine 
Replacement 
(N = 446)
Total 
(N = 884)
Median age (IQR) — yr 41 (33–53) 41 (33–51) 41 (33–52)
Female sex — no. (%) 211 (48.2) 213 (47.8) 424 (48.0)
Employed — no. (%) 299 (68.3) 316 (70.9) 615 (69.6)
Entitled to free prescriptions — no. (%) 181 (41.3) 179 (40.1) 360 (40.7)
Median no. of cigarettes per day (IQR) 15 (10–20) 15 (10–20) 15 (10–20)
Median expired carbon monoxide level (IQR) — ppm 20 (13–27) 21 (13–28) 20 (13–28)
Score on the Fagerström Test for Cigarette Dependence† 4.5±2.5 4.6±2.4 4.6±2.4
Past use of nicotine replacement — no. (%) 328 (74.9) 334 (74.9) 662 (74.9)
Past use of e-cigarettes — no. (%) 186 (42.5) 181 (40.6) 367 (41.5)
*  Plus–minus values are means ±SD. There were no significant differences between the trial groups. IQR denotes inter-
quartile range. Data on additional characteristics are provided in Table S1 in the Supplementary Appendix.
†  Scores range from 1 to 10, with higher scores indicating greater dependence.
Table 1. Characteristics of the Participants at Baseline.*
Outcome
E-Cigarettes 
(N = 438)
Nicotine 
Replacement 
(N = 446)
Primary Analysis:  
Relative Risk  
(95% CI)†
Sensitivity Analysis:  
Adjusted Relative Risk  
(95% CI)
Primary outcome: abstinence at 52 wk — no. (%) 79 (18.0) 44 (9.9) 1.83 (1.30–2.58) 1.75 (1.24–2.46)‡
Secondary outcomes
Abstinence between wk 26 and wk 52 — no. (%) 93 (21.2) 53 (11.9) 1.79 (1.32–2.44) 1.82 (1.34–2.47)§
Abstinence at 4 wk after target quit date — no. (%) 192 (43.8) 134 (30.0) 1.45 (1.22–1.74) 1.43 (1.20–1.71)¶
Abstinence at 26 wk after target quit date — no. (%) 155 (35.4) 112 (25.1) 1.40 (1.14–1.72) 1.36 (1.15–1.67)‡
Carbon monoxide–validated reduction in smoking of 
≥50% in participants without abstinence between 
wk 26 and wk 52 — no./total no. (%)
44/345 (12.8) 29/393 (7.4) 1.75 (1.12–2.72) 1.73 (1.11–2.69)‖
*  Abstinence at 52 weeks was defined as a self-report of smoking no more than five cigarettes from 2 weeks after the target quit date, validated 
biochemically by an expired carbon monoxide level of less than 8 ppm at 52 weeks. Abstinence between week 26 and week 52 was defined 
as a self-report of smoking no more than five cigarettes between week 26 and week 52, plus an expired carbon monoxide level of less than  
8 ppm at 52 weeks. Abstinence at 4 weeks was defined as a self-report of no smoking from 2 weeks after the target quit date, plus an ex-
pired carbon monoxide level of less than 8 ppm at 4 weeks. Abstinence at 26 weeks was defined as a self-report of smoking no more than 
five cigarettes from 2 weeks after the target quit date to 26 weeks; there was no validation by expired carbon monoxide level.
†  The analysis was adjusted for trial center only.
‡  The analysis was adjusted for trial center, marital status, age at smoking initiation, and score on the Fagerström Test for Cigarette 
Dependence.
§  The analysis was adjusted for trial center, age, score on the Fagerström Test for Cigarette Dependence, and age at smoking initiation.
¶  The analysis was adjusted for trial center, education level, partner who smokes (yes or no), and score on the Fagerström Test for Cigarette 
Dependence.
‖  The analysis was adjusted for trial center, sex, age, and partner who smokes (yes or no).
Table 2. Abstinence Rates at Different Time Points and Smoking Reduction at 52 Weeks.*
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was not achieved, more had a carbon monoxide–
validated reduction of smoking by at least 50% 
in the e-cigarette group than in the nicotine-
replacement group (Table 2). Time to relapse 
and relapse rates at 52 weeks among partici-
pants with sustained abstinence at 4 weeks did 
not differ substantially between the two trial 
groups (hazard ratio for time to relapse, 1.14; 
95% CI, 0.96 to 1.34; relative risk of relapse at 
52 weeks, 1.27; 95% CI, 0.93 to 1.73).
Treatment Adherence and Ratings and Effects 
on Withdrawal Symptoms
Overall adherence was similar in the two groups, 
but e-cigarettes were used more frequently and 
for longer than nicotine replacement (Table 3). 
In the nicotine-replacement group, 88.1% of 
participants used nicotine-replacement combi-
nations. In the e-cigarette group, practically all 
participants used refillable e-cigarettes (Table S4 
in the Supplementary Appendix).
Among participants with 1-year abstinence, 
80% (63 of 79) were using e-cigarettes at 52 
weeks in the e-cigarette group and 9% (4 of 44) 
were using nicotine replacement in the nicotine-
replacement group. Further details of product 
use (including the use of nonassigned products) 
are provided in the Supplementary Appendix, 
including Tables S4 and S5.
Both e-cigarettes and nicotine-replacement 
products were perceived to be less satisfying 
than cigarettes. However, e-cigarettes provided 
greater satisfaction and were rated as more 
helpful to refrain from smoking than nicotine-
replacement products (Table S6 in the Supple-
mentary Appendix).
Among participants with abstinence at 1 week 
after their quit date as well as participants with 
abstinence at 4 weeks, those in the e-cigarette 
group had less severe urges to smoke than did 
those in the nicotine-replacement group (Table 4). 
They also reported a smaller increase from base-
line in irritability, restlessness, and inability to 
concentrate than those in the nicotine-replace-
ment group during the first week of abstinence. 
Between-group differences in hunger and depres-
sion were in the same direction but less substan-
tial. By week 4, participants in either group who 
were abstinent reported little withdrawal discom-
fort (Table S7 in the Supplementary Appendix).
Variable
E-Cigarettes 
(N = 438)
Nicotine 
Replacement 
(N = 446)
Median no. of contacts completed (IQR)* 5 (4–5) 5 (4–5)
Maximum no. of contacts completed — no. of participants (%)
1 8 (1.8) 10 (2.2)
2 25 (5.7) 40 (9.0)
3 38 (8.7) 45 (10.1)
4 86 (19.6) 106 (23.8)
5 281 (64.2) 245 (54.9)
Use of assigned products during the initial 4 wk†
Median no. of days on which product was used (IQR) 28 (25–28) 24 (19–27)
Daily use during the entire 4 wk — no. (%) 232 (53.0) 46 (10.3)
Median no. of days on which product was used in past wk (IQR)‡ 7 (7–7) 6.5 (3.5–7)
Use of assigned products at 26 wk — no. (%) 180 (41.1) 33 (7.4)
Use of assigned products at 52 wk — no. (%) 173 (39.5) 19 (4.3)
*  The maximum number of contacts was five: at the target quit date, 1 week, 4 weeks, 26 weeks, and 52 months.
†  For use of assigned products, missing information was imputed from the information from the next weekly behavioral-
support consultation, if available (e.g., for missing information at consultation 3, information was taken from consulta-
tion 4).
‡  The results were similar for weeks 1 through 4.
Table 3. Attendance and Treatment Adherence.
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Safety Evaluation
Two participants died during the trial. One died 
from ischemic heart disease in the e-cigarette 
group and one from traumatic spine injury in 
the nicotine-replacement group.
There were 27 serious adverse events in the 
e-cigarette group and 22 in the nicotine-replace-
ment group (Table S8 in the Supplementary Ap-
pendix). No serious adverse event in either group 
was classified by the trial clinician as being re-
lated to product use, but we noted 1 respiratory 
event in the nicotine-replacement group and 5 in 
the e-cigarette group (2 in participants who were 
smoking and not vaping, 2 in participants who 
were smoking and vaping, and 1 in a participant 
whose status with respect to smoking and vap-
ing was not known) (see the Supplementary Ap-
pendix).
Of the prespecified adverse reactions of inter-
est, nausea was reported more frequently in the 
nicotine-replacement group (37.9%, vs. 31.3% in 
the e-cigarette group) and throat or mouth irri-
tation more frequently in the e-cigarette group 
(65.3%, vs. 51.2% in the nicotine-replacement 
group). There was little difference between the 
two groups in the percentage of participants 
reporting severe nausea (6.6% in the e-cigarette 
group and 6.5% in the nicotine-replacement 
group) or severe throat or mouth irritation (5.9% 
and 3.9%, respectively) (Tables S9 and S10 in the 
Supplementary Appendix).
Regarding the prespecified respiratory symp-
toms of interest, the incidence of cough and 
phlegm production declined in both trial groups 
from baseline to 52 weeks. However, among 
participants who reported cough or phlegm at 
baseline, significantly more were symptom-free 
at the 52-week follow-up in the e-cigarette group 
than in the nicotine-replacement group (Table 5). 
To determine whether this was due to the high-
er abstinence rate in the e-cigarette group, we 
ran an exploratory analysis that controlled for 
Variable 1 Wk after Quit Date
Mean Difference 
(95% CI) 4 Wk after Quit Date
Mean Difference 
(95% CI)
E-Cigarettes 
(N = 158)
Nicotine 
Replacement 
(N = 131)
E-Cigarettes 
(N = 186)
Nicotine 
Replacement 
(N = 132)
Score for frequency of urge 2.5±1.1 2.8±0.9 −0.4 (−0.6 to −0.1) 1.9±0.9 2.2±0.8 −0.3 (−0.5 to −0.1)
Score for strength of urge 2.7±1.1 3.2±1.0 −0.5 (−0.7 to −0.2) 2.1±1.1 2.4±1.0 −0.3 (−0.6 to −0.1)
Composite urge score 2.6±1.0 3.0±0.9 −0.4 (−0.6 to −0.2) 2.0±1.0 2.3±0.9 −0.3 (−0.5 to −0.1)
*  Plus–minus values are means ±SD. Scores for frequency of urge ranged from 1 (not at all) to 6 (all the time). Scores for strength of urge 
ranged from 1 (no urges) to 6 (extremely strong). The composite score (range, 1 to 6, with higher scores indicating more severe urges) is 
an average of the frequency and strength scores.
Table 4. Urges to Smoke in Participants with Abstinence at 1 Week or 4 Weeks after Quit Date.*
Symptom E-Cigarettes (N = 315) Nicotine Replacement (N = 279) Relative Risk (95% CI)†
Baseline 52 Weeks Baseline 52 Weeks
number (percent)
Shortness of breath 120 (38.1) 66 (21.0) 92 (33.0) 64 (22.9) 0.9 (0.7–1.1)
Wheezing 102 (32.4) 74 (23.5) 86 (30.8) 59 (21.1) 1.1 (0.8–1.4)
Cough 173 (54.9) 97 (30.8) 144 (51.6) 111 (39.8) 0.8 (0.6–0.9)
Phlegm 137 (43.5) 79 (25.1) 121 (43.4) 103 (36.9) 0.7 (0.6–0.9)
*  Symptoms were assessed by asking whether participants had the symptom (yes or no).
†  Relative risk was calculated by means of logistic regression. Symptoms at 52 weeks were regressed onto trial group, 
with adjustment for baseline symptoms and trial center.
Table 5. Respiratory Symptoms at Baseline and at 52 Weeks.*
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abstinence status at 52 weeks. This did not 
change the results (relative risk for cough, 0.8; 
95% CI, 0.6 to 0.9; relative risk for phlegm, 0.7; 
95% CI, 0.6 to 0.9).
Discussion
E-cigarettes were more effective for smoking 
cessation than nicotine-replacement therapy in 
this randomized trial. This is particularly note-
worthy given that nicotine replacement was used 
under expert guidance, with access to the full 
range of nicotine-replacement products and with 
88.1% of participants using combination treat-
ments.11
Our trial showed a stronger effect of e-ciga-
rettes than previous trials.5,12,13 This could be 
due to the inclusion of smokers seeking help in 
quitting, the provision of face-to-face support, 
and the use of refillable e-cigarettes with free 
choice of e-liquids. Previous trials provided lim-
ited or no face-to-face support and used first-
generation cartridge products. Refillable devices 
are generally more efficient at nicotine delivery.14
The trial provides some indications of why 
e-cigarettes had better results than nicotine-
replacement treatments. As in previous stud-
ies,5,15 e-cigarettes were more effective in allevi-
ating tobacco withdrawal symptoms and received 
better ratings than nicotine-replacement ther-
apy. They may also have allowed better tailoring 
of nicotine dose to individual needs.
The rate of continuing e-cigarette use was 
fairly high. This can be seen as problematic if 
e-cigarette use for a year signals ongoing long-
term use, which may pose as-yet-unknown health 
risks. On the positive side, ongoing e-cigarette 
use may ameliorate withdrawal symptoms, such 
as constipation,16 mouth ulcers,17 and weight 
gain,18 and continue to provide some of the 
positive subjective effects previously derived 
from smoking.19 Provided that ongoing e-ciga-
rette use has similar effects to long-term nico-
tine-replacement use, for heavy smokers with a 
high risk of relapse, long-term e-cigarette use 
may also assist with preventing relapse.20 Among 
participants in our trial in whom full abstinence 
was not achieved, those in the e-cigarette group 
were more likely to reduce their smoke intake 
than those in the nicotine-replacement group, 
but it is unclear whether this affects future ab-
stinence.
E-cigarettes caused more throat or mouth ir-
ritation, and nicotine replacement caused more 
nausea; these effects were mostly mild. There were 
mixed signals regarding the effects of e-cigarettes 
on the respiratory system. More participants in the 
e-cigarette group than in the nicotine-replace-
ment group reported respiratory serious adverse 
events, although the difference was not signifi-
cant and some of the affected participants were 
not vaping. Meanwhile, we detected positive ef-
fects of e-cigarette use on some respiratory out-
comes. Similar positive effects were reported 
previously. A switch to e-cigarettes was accom-
panied by a reduction in respiratory infections in 
an online survey,21 and two case studies described 
nonsmokers with chronic throat and nose infec-
tions that resolved after they started to vape. 
Antibacterial effects of propylene glycol and 
glycerin were suggested as possible explana-
tions.22,23 (For more on e-cigarettes and the respi-
ratory system, see the Supplementary Appendix.)
The trial had several limitations. Product as-
signments could not be blinded. Positive expec-
tations have limited effects on long-term absti-
nence, but if nicotine replacement was seen as 
an inferior option, participants in the nicotine-
replacement group could have put less effort into 
their quit attempt than those in the e-cigarette 
group. We tried to limit expectation effects by 
recruiting only participants with no strong prod-
uct preference. Abstinence rates in the nicotine-
replacement group were also at least as high as 
in usual practice24 (see the Supplementary Appen-
dix). Nevertheless, lack of blinding could affect 
the results. Carbon monoxide validation detects 
smoking only over the past 24 hours, so there 
may have been some false negative results. Sev-
eral participants in the nicotine-replacement 
group used e-cigarettes during the trial, but this 
would dilute rather than amplify any effects of 
e-cigarettes. The 1-year follow-up rate of 79% 
was similar to the rates of 78%,19 79%,5 and 
75%20 observed in other studies involving the 
same general population and setting. Achieving 
higher follow-up rates among smokers engaged 
in face-to-face treatment is difficult, because they 
tend to feel embarrassed if they do not quit, and 
some avoid further contact. Multiple imputation 
showed consistent results; nevertheless, incom-
plete follow-up represents another limitation of 
the trial.
The findings are likely to be valid for depen-
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dent smokers who seek help but may not be 
generalizable to smokers who are less dependent 
or who try e-cigarettes for reasons other than 
quitting smoking. In addition, they may not be 
generalizable to less effective first-generation 
e-cigarettes. Moreover, not all service clients 
want e-cigarettes. In a previous study, 69% ac-
cepted the offer of an e-cigarette starter pack.25 
(For comparison, 57% of service clients opt for 
nicotine replacement and 25% for varenicline.26)
Further trials are needed to determine whether 
our results generalize outside the U.K. services. 
In addition, e-cigarette studies are needed that 
compare different levels of support. This is im-
portant for focusing public health messages on 
either encouraging smokers to switch to e-ciga-
rette use within support services or recommend-
ing use with less intensive or no support.
In our trial, refillable e-cigarettes had greater 
efficacy than nicotine-replacement therapy, even 
though nicotine replacement was provided in 
combinations and under expert guidance.
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